BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 17543783)

  • 21. Sirolimus as primary immunosuppressant for calcineurin inhibitor-related renal insufficiency after liver transplantation.
    Yang YJ; Li LX; He Q; Fan H; Jin ZK; Lang R; Kou JT; Li P; Xie DH; Chen DZ
    Hepatobiliary Pancreat Dis Int; 2007 Aug; 6(4):376-8. PubMed ID: 17690032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sirolimus-based, calcineurin-inhibitor sparing immunotherapy, long-term (6-year) results.
    Conti DJ; Petrov R; Elbalhoul O; Gallichio M
    Transpl Immunol; 2008 Nov; 20(1-2):12-3. PubMed ID: 18793727
    [TBL] [Abstract][Full Text] [Related]  

  • 23. De novo immunosuppression with sirolimus and tacrolimus in heart transplant recipients compared with cyclosporine and mycophenolate mofetil: a one-year follow-up analysis.
    Zucker MJ; Baran DA; Arroyo LH; Goldstein DJ; Neacy C; Mele L; Weinberg AD; Prendergast TW; Ribner HS
    Transplant Proc; 2005 Jun; 37(5):2231-9. PubMed ID: 15964386
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency.
    Yang YJ; Chen DZ; Li LX; Kou JT; Lang R; Jin ZK; Han DD; He Q
    Transplant Proc; 2008 Jun; 40(5):1541-4. PubMed ID: 18589147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sirolimus as an alternative to anticalcineurin therapy in heart transplantation: experience of a single center.
    Fernandez-Valls M; Gonzalez-Vilchez F; de Prada JA; Ruano J; Ruisanchez C; Martin-Duran R
    Transplant Proc; 2005 Nov; 37(9):4021-3. PubMed ID: 16386615
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of early conversion from tacrolimus to sirolimus on chronic allograft changes in kidney recipients on rapid steroid withdrawal.
    Heilman RL; Cortese C; Geiger XJ; Younan K; Wadei HM; Mai ML; Reddy KS; Gonwa TA
    Transplantation; 2012 Jan; 93(1):47-53. PubMed ID: 22067270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Late acute cardiac allograft rejection: new therapeutic options?
    Schweiger M; Wasler A; Prenner G; Tripolt M; Schwarz M; Tscheliessnigg KH
    Transplant Proc; 2005 Dec; 37(10):4528-31. PubMed ID: 16387161
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients.
    Tenderich G; Fuchs U; Zittermann A; Muckelbauer R; Berthold HK; Koerfer R
    Clin Transplant; 2007; 21(4):536-43. PubMed ID: 17645716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Replacing calcineurin inhibitors with mTOR inhibitors in children.
    Sindhi R; Seward J; Mazariegos G; Soltys K; Seward L; Smith A; Kosmach B; Venkataramanan R
    Pediatr Transplant; 2005 Jun; 9(3):391-7. PubMed ID: 15910398
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rejection episodes and 3-year graft survival under sirolimus and tacrolimus treatment after adult intestinal transplantation.
    Lauro A; Dazzi A; Ercolani G; Zanfi C; Golfieri L; Amaduzzi A; Cucchetti A; La Barba G; Grazi GL; D'Errico A; Vivarelli M; Cescon M; Varotti G; Del Gaudio M; Ravaioli M; Di Simone M; Faenza S; Pironi L; Pinna AD
    Transplant Proc; 2007 Jun; 39(5):1629-31. PubMed ID: 17580204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
    DuBay D; Smith RJ; Qiu KG; Levy GA; Lilly L; Therapondos G
    Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Late steroid withdrawal after heart transplantation and incidence of acute rejection.
    Crespo-Leiro MG; Paniagua MJ; Franco R; Marzoa R; Grille Z; Naya C; Barge E; Rios R; Rodríguez JA; Calviño R; Cuenca JJ; Castro-Beiras A
    Transplant Proc; 2007 Sep; 39(7):2372-4. PubMed ID: 17889193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Avoidance of calcineurin inhibitors with use of proliferation signal inhibitors in de novo heart transplantation with renal failure.
    González-Vílchez F; de Prada JA; Exposito V; García-Camarero T; Fernández-Friera L; Llano M; Ruano J; Martín-Durán R
    J Heart Lung Transplant; 2008 Oct; 27(10):1135-41. PubMed ID: 18926406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Excellent long-term results in de novo renal transplant recipients treated with proliferation signal inhibitors and reduced calcineurin inhibitors exposure.
    Carmellini M; Collini A; Ruggieri G; Garosi G; Bernini M
    Transplant Proc; 2008; 40(6):1858-61. PubMed ID: 18675070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapamycin at six years can exhibit normal renal function without proteinuria or neoplasia after renal transplantation. A single-center experience.
    Nungaray N; Arriola M; Gutierrez MJ; Oliva E; Hernández E; Gonzalez E; Andres A; Morales JM
    Transplant Proc; 2005 Nov; 37(9):3727-8. PubMed ID: 16386519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis.
    Viganò M; Tuzcu M; Benza R; Boissonnat P; Haverich A; Hill J; Laufer G; Love R; Parameshwar J; Pulpón LA; Renlund D; Abeywickrama K; Cretin N; Starling RC; Eisen HJ;
    J Heart Lung Transplant; 2007 Jun; 26(6):584-92. PubMed ID: 17543781
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
    Raichlin E; Khalpey Z; Kremers W; Frantz RP; Rodeheffer RJ; Clavell AL; Edwards BS; Kushwaha SS
    Transplantation; 2007 Aug; 84(4):467-74. PubMed ID: 17713429
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of sirolimus alone with sirolimus plus tacrolimus in type 1 diabetic recipients of cultured islet cell grafts.
    Gillard P; Ling Z; Mathieu C; Crenier L; Lannoo M; Maes B; Roep B; Gorus F; Pipeleers D; Keymeulen B
    Transplantation; 2008 Jan; 85(2):256-63. PubMed ID: 18212631
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A; Töz H; Sen S; Alkan FT; Nart A; Aykas A; Doğan M; Postaci H; Sahin T; Simşek C
    Transplant Proc; 2009 Mar; 41(2):756-63. PubMed ID: 19328973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.